Efficacy and safety of adjunctive cilostazol to clopidogrel-treated diabetic patients with symptomatic lower extremity artery disease in the prevention of ischemic vascular events

Diabetes - General

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

Lancet Diabetes Endocrinol.

Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, Murphy SA, Kuder JF, Gouni-Berthold I, Lewis BS, Handelsman Y, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR

doi: 10.1016/

RECOMMENDED

Type 2 Diabetes

Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin - A DEVOTE subanalysis (DEVOTE 10)

Diabetes Obes Metab.

Brown-Frandsen K, Emerson SS, McGuire DK, Pieber TR, Poulter NR, Pratley RE, Zinman B, Ranthe MF, Grøn R, Lange M, Moses AC, Őrsy P, Buse JB, DEVOTE Study Group

doi: 10.1111/dom.13677.

COMMENTED

Diabetes - GeneralType 2 DiabetesGlycemic Control

A Randomized Clinical Trial of the Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in Patients with Type 2 Diabetes Mellitus and Mild Renal Insufficiency: The CompoSIT-R Study

Diabetes Obes Metab.

Scott R, Morgan J, Zimmer Z, Lam RLH, O'Neill EA, Kaufman KD, Engel SS, Raji A

doi: 10.1111/dom.13473.

Glycemic Control

Efficacy and Safety of Diacerein in Patients With Inadequately Controlled Type 2 Diabetes: A Randomized Controlled Trial

Diabetes Care.

Cardoso CRL, Leite NC, Carlos FO, Loureiro AA, Viegas BB, Salles GF

doi: 10.2337/dc17-0374.

COMMENTED

Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants

★ 3 Recommended by Prof. Dr Isabella Sudano, Faculty Member

★ 2 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Lancet Diabetes Endocrinol.

Wang N, Fulcher J, Abeysuriya N, Park L, Kumar S, Di Tanna GL, Wilcox I, Keech A, Rodgers A, Lal S

doi: 10.1016/S2213-8587(19)30388-2.

Diabetes - GeneralType 2 DiabetesGlycemic Control

Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial

Diabetes Care.

Jabbour SA, Frìas JP, Hardy E, Ahmed A, Wang H, Öhman P, Guja C

doi: 10.2337/dc18-0680.

COMMENTED

Diabetes - GeneralType 2 DiabetesDiabetes and Pregnancy

Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study

Diabetologia.

Aroda VR, Knowler WC, Crandall JP, Perreault L, Edelstein SL, Jeffries SL, Molitch ME, Pi-Sunyer X, Darwin C, Heckman-Stoddard BM, Temprosa M, Kahn SE, Nathan DM; Diabetes Prevention Program Research Group

doi: 10.1007/s00125-017-4361-9.

Diabetes - GeneralType 2 Diabetes

Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial

Diabetes Obes Metab.

Harris SB, Kocsis G, Prager R, Ridge T, Chandarana K, Halladin N, Jabbour S

doi: 10.1111/dom.12892.

Diabetes - GeneralType 2 DiabetesGlycemic ControlLipids

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients with Type 2 Diabetes: 10-year Follow-up of a Randomized Controlled Trial.

Circulation

Saito Y, Okada S, Ogawa H, Soejima H, Sakuma M, Nakayama M, Doi N, Jinnouchi H, Waki M, Masuda I, Morimoto T

doi: 10.1161/CIRCULATIONAHA.

Related content

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin - A DEVOTE subanalysis (DEVOTE 10)

A Randomized Clinical Trial of the Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in Patients with Type 2 Diabetes Mellitus and Mild Renal Insufficiency: The CompoSIT-R Study

Efficacy and Safety of Diacerein in Patients With Inadequately Controlled Type 2 Diabetes: A Randomized Controlled Trial

Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants

Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial

Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study

Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients with Type 2 Diabetes: 10-year Follow-up of a Randomized Controlled Trial.